The mean 24-h HR increase adjusted for baseline and placebo values was 1.3 bpm [22]
Sodiumglucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
10.1016/j.clnu.2009.05.011 11 BomfimT
In the landmark STEP 1 trial (Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding and colleagues, New England Journal of Medicine , 2021), 1,961 adults who took weekly semaglutide (2.4 mg) plus lifestyle support lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo, and 86% achieved at least 5% weight loss
In these 18- and 24-week studies, among patients who were not on an antihyperglycemic agent at study entry, the reductions from baseline in A1C were -0.7% and -0.8%, respectively, for those given Januvia, and -0.1% and -0.2%, respectively, for those given placebo
Huanggang Huayang Pharmaceutical Co., Ltd